Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray Medical) (300760)

Equity Research Report | Industry: Diversified Medical Devices | Report date: September 13, 2026 | As of the September 11, 2026 close; this report primarily uses the closing-market data methodology of Dabanke, with a closing price of RMB 162.73. Minor discrepancies exist among market-data sources. Investing displayed RMB 163.08 on the same day, possibly due to refresh timing, adjustment methodology, or data-processing differences.

This report was automatically compiled by AI based on publicly available information and is for reference only. It does not constitute investment advice.

1. Executive Summary

Mindray Medical faced operating pressure in 2025, but signs of revenue recovery emerged in the first half of 2026: operating revenue was RMB 17.747 billion, up 6.00% year on year, while net profit attributable to the parent was RMB 4.797 billion, down 5.37% year on year. Revenue in the second quarter was approximately RMB 9.395 billion and net profit attributable to the parent was approximately RMB 2.467 billion, representing year-on-year growth of 10.45% and approximately 1.10%, respectively. The recovery was primarily driven by international business. International revenue was approximately RMB 9.471 billion in the first half, up 13.67% year on year, while domestic revenue was approximately RMB 8.276 billion, down 1.61%. Accordingly, the key issue remains whether the domestic business can continue to bottom out and whether profit-margin recovery can be sustained.

The company exhibits the characteristics of a diversified platform medical-device manufacturer. Its businesses cover in-vitro diagnostics, patient monitoring and life support, medical imaging and minimally invasive surgery, minimally invasive intervention, animal healthcare and other emerging areas. R&D investment was approximately RMB 3.929 billion in 2025, accounting for approximately 11.8% of revenue. Overseas revenue accounted for approximately 53% of 2025 revenue, and products are sold in more than 190 countries and regions worldwide. Coordination across product lines, the “equipment + reagents and consumables + software + solutions” model, and hospital-installed-base and service capabilities provide a foundation for overseas expansion, cross-selling and volume growth in emerging businesses.

In 2025, operating revenue was RMB 33.282 billion, down 9.38% year on year, while net profit attributable to the parent was RMB 8.136 billion, down 30.28%. Gross margin and net margin fell to 60.32% and 25.39%, respectively, with pressure on profitability exceeding the decline in revenue. Domestic revenue fell 22.97%. The company identified medical-equipment procurement cycles, DRG/DIP reforms, centralized volume-based procurement of IVD products, mutual recognition of test results and medical-service price governance as sources of pressure. Some domestic receivables also had relatively long aging periods, and collection quality remains a point of concern.

As of September 11, 2026, the stock closed at RMB 162.73, below the major short- and medium-term moving averages. MACD was negative, and estimated net outflow of major funds was approximately RMB 154 million, indicating weak short-term technical momentum. However, the stock remained above MA200 of approximately RMB 157.92, while Williams %R indicated a degree of oversold conditions. The current trailing P/E ratio is approximately 24–25x. The valuation already incorporates expectations for domestic-business recovery, international growth and volume expansion in emerging businesses; the degree to which subsequent earnings materialize will affect valuation digestion.

2. Company Overview

2.1 Basic Information

2.2 Principal Businesses and Product Portfolio

• In-vitro diagnostics (IVD): Includes hematology analysis, biochemical analysis, immunoassay, microbiological testing, coagulation testing, urinalysis, IVD reagents and laboratory-automation solutions, using an “instruments + reagents + consumables + services” model.
• Patient monitoring and life support: Includes patient monitors, defibrillators, anesthesia machines, ventilators, ECG machines, infusion systems, operating tables, surgical lights, ceiling pendants and bridges, as well as integrated perioperative and intensive-care-unit solutions.
• Medical imaging: Includes ultrasound, digital X-ray imaging systems, MRI-related products and imaging-informatics solutions. The company continues to expand into high-end ultrasound, digital imaging and integrated imaging solutions.
• Emerging businesses: Primarily include minimally invasive surgery, minimally invasive intervention and animal healthcare. The 2025 annual report presents emerging businesses as a separate category.
• Other businesses: Revenue of RMB 110 million in 2025, accounting for approximately 0.33%.
• 2025 revenue mix: IVD revenue of RMB 12.241 billion, accounting for 36.78%, with a gross margin of approximately 58.33%; patient monitoring and life-support revenue of RMB 9.837 billion, accounting for 29.56%, with a gross margin of approximately 59.37%; medical-imaging revenue of RMB 5.717 billion, accounting for 17.18%, with a gross margin of approximately 63.05%; emerging-business revenue of RMB 5.378 billion, accounting for 16.16%, with a gross margin of approximately 63.74%.
• The three traditional businesses generated aggregate revenue of approximately RMB 27.795 billion in 2025, accounting for approximately 83.5% of operating revenue; emerging businesses accounted for more than 16%. Product-level revenue definitions were adjusted between 2024 and 2025, so some year-on-year comparisons should not be made mechanically.

2.3 Position in the Upstream and Downstream Value Chain and Cost-Profit Structure

Mindray Medical is positioned in the midstream-to-downstream portion of the medical-device value chain. It possesses capabilities in R&D, registration, manufacturing, supply-chain integration, channel services and hospital installation. It directly provides equipment, reagents, consumables, software and integrated solutions to hospitals and other medical institutions. It is therefore a diversified platform medical-device company rather than a pure midstream contract manufacturer.

• Major purchases of electronic and electrical components include chips, sensors, displays, power modules, circuit boards, connectors, communications components and control components.
• Major purchases of structural and mechanical parts include metal structures, plastic parts, machined parts, molds, housings, brackets and precision mechanical components.
• Imaging-related purchases include probes, optical components, imaging modules and other core components; fluidic and functional components include pumps, valves, tubing, gas-path assemblies and consumable components.
• IVD-related purchases include reagent raw materials, calibrators, controls, packaging materials and laboratory consumables, as well as packaging materials, auxiliary materials and production consumables.
• The company uses standard-component procurement, customized-component procurement and outsourced-component procurement. The 2025 annual report stated that the company had more than 1,000 suppliers, with most maintaining long-term relationships.
• According to the 2025 annual report, procurement from the five largest suppliers totaled RMB 799 million, accounting for 6.06% of annual procurement. The largest single supplier accounted for 1.93%; none of the five largest suppliers involved related-party procurement. Overall supplier concentration is low, and ordinary electronic components, structural parts and general materials have some potential for supplier substitution.
• High-performance chips, sensors, core imaging components, precision optical components and special reagent raw materials may involve long qualification cycles, limited alternative suppliers or import dependence. However, public disclosures do not adequately specify the procurement share of each type of key component; overall supplier concentration cannot be used to infer that the company has complete bargaining power across all upstream links.
• The company has strong scale-procurement capabilities for ordinary components and standard parts, but relatively limited bargaining power for high-end chips, core imaging components and special diagnostic raw materials. Supply-chain security depends on supplier qualification, domestic substitution and in-house R&D capabilities.
• Downstream customers include public hospitals, private hospitals, medical groups, clinic chains, third-party medical-testing laboratories, government healthcare projects and public-health institutions, overseas hospitals, medical groups, GPO procurement organizations, distributors, animal hospitals and veterinary institutions.
• The Chinese market is primarily distributor-led, supplemented by direct sales. The U.S. market is primarily direct-sales based, with the company directly participating in tenders and commercial negotiations involving hospital groups, IDNs and GPOs. European and other overseas markets use a mix of direct sales and distribution, or are primarily distribution-based.
• Sales to the five largest customers totaled RMB 1.933 billion in 2025, accounting for 5.80% of annual sales; the largest single customer accounted for 2.38%. The annual report stated that no single major customer accounted for more than 10% of sales revenue. This is based on the 2025 annual report; the research notes did not provide data for other years for cross-comparison.
• Hospital and government procurement generally determine prices through tendering, centralized procurement or project procurement. Hospital budgets, DRG/DIP payment reforms, equipment-replacement cycles and fiscal conditions affect procurement timing. IVD business is also affected by centralized reagent procurement, mutual recognition of test results and medical-service price governance.
• The company has some bargaining power in high-end equipment, hospital-wide solutions and the “instruments + reagents” closed loop. Once equipment is installed, changing suppliers requires revalidation, personnel training, data integration and adjustments to clinical workflows, giving high-end and installed-base customers a degree of stickiness.
• Domestic revenue fell 22.97% in 2025. The company linked the decline to DRG/DIP reforms, centralized volume-based procurement of reagents, mutual recognition of test results and medical-service price governance. Overseas revenue rose 7.40% over the same period, although overseas operations continue to face pressure from branding, distribution, certification and local-service costs.
• Revenue classification was adjusted in 2025, with emerging businesses presented separately; consequently, some year-on-year product-level comparisons between 2024 and 2025 are affected by changes in definition.
• As of December 31, 2025, accounts receivable were RMB 3.408 billion, representing 5.75% of total assets and approximately 10.24% of 2025 operating revenue; receivables turnover days were approximately 35.84 days. Inventory was RMB 5.004 billion, representing 8.44% of total assets, with inventory turnover days of approximately 133.03 days. Payables for materials were RMB 3.242 billion, and contract liabilities were RMB 3.001 billion, including advance receipts and deferred revenue. Contract liabilities and materials payables provide some funding support or represent upstream funding obtained by the company. However, the balance of domestic accounts receivable aged more than 360 days was relatively high, and the corresponding bad-debt provision ratio reached 97.16%, indicating long collection cycles from some domestic hospitals or channels. This does not mean that the company has absolute bargaining power over all downstream customers. Operating metrics such as receivables turnover days are sourced from public financial databases, whose calculation methods may differ from those used in the annual report. Balance-sheet balances and aging data should be based on the audited 2025 annual report.
• Upstream, the 2025 annual report disclosed that the five largest suppliers accounted for 6.06% of procurement and the largest single supplier accounted for 1.93%. Downstream, the five largest customers accounted for 5.80% of sales in 2025 and the largest single customer accounted for 2.38%; no single major customer accounted for more than 10% of sales revenue. All of these concentration figures are based on the 2025 annual report. The research notes did not provide multi-year data, so cross-year verification was not possible. Detailed supplier concentration for key chips, core imaging components and special reagent raw materials was also not adequately disclosed.

Mindray Medical is positioned in the midstream-to-downstream portion of the medical-device value chain. Its value derives from R&D and registration, quality manufacturing systems, brand and distribution channels, hospital installation, recurring purchases of IVD reagents and consumables, and integrated solutions, rather than from commodities or simple processing. The key to further margin improvement lies in upgrading high-end products, breaking through with high-end overseas customers, expanding IVD installations and recurring purchases of reagents and consumables, scaling emerging businesses, localizing core components and increasing penetration of hospital-wide solutions. Short-term pressure comes from domestic hospital procurement budgets, IVD centralized procurement, equipment-price competition, overseas selling expenses and supply risks involving high-end core components.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

The latest formally disclosed financial report is the 2026 Interim Report, announced on August 28, 2026, with data as of June 30, 2026. The figures are reviewed company-disclosed data. Net profit attributable to the parent excluding non-recurring items was RMB 4.785 billion in the first half of 2026, down 3.32% year on year; consolidated net profit was RMB 5.047 billion, down approximately 3.55% year on year; net cash flow from operating activities was RMB 4.877 billion, up 24.35% year on year; basic EPS was RMB 3.9584.

Mindray Medical’s first-half 2026 performance was characterized by revenue recovery while profits remained under pressure. Second-quarter revenue and net profit attributable to the parent returned to positive year-on-year growth and improved significantly from the first quarter, indicating marginal operating recovery. International revenue was approximately RMB 9.471 billion, up 13.67% year on year and accounting for approximately 53% of operating revenue; domestic revenue was approximately RMB 8.276 billion, down 1.61% year on year. International business was the main source of current revenue growth. Some institutions estimated first-half net-profit growth at approximately 8.68% after excluding foreign-exchange effects, but this is an institution-adjusted estimate rather than a statutory company-reporting measure. Revenue and profit both declined significantly in 2025, mainly due to the domestic medical-equipment procurement cycle, pressure on IVD pricing and demand, and foreign-exchange factors.

3.2 Earnings Forecasts

According to Tonghuashun F10, 31 institutions had issued forecasts for the company’s 2026 results during the six months ended September 11, 2026. The 2026–2028 net-profit and EPS figures below are the average of a nine-institution sample publicly listed by Stockstar. They represent the average of a public institutional sample and are not equivalent to exchange or company guidance, nor do they necessarily cover all sell-side institutions. The average 2026 operating-revenue forecast is approximately RMB 35.711 billion, implying year-on-year growth of approximately 7.3% from actual 2025 revenue of RMB 33.282 billion; complete average operating-revenue forecasts for 2027–2028 were not disclosed.

3.3 Valuation and Institutional Ratings

The latest trading day was September 11, 2026. The closing price was approximately RMB 163.08, total market capitalization was approximately RMB 197.8 billion, trailing P/E was approximately 25.2x, forward P/E was approximately 20.6x and P/B was approximately 4.9x. Some platforms showed a P/E (TTM) of approximately 25.16x and P/B of approximately 4.88x. Based on the average EPS of the nine-institution public sample, the current share price corresponds to forecast P/E ratios of approximately 23.1x, 20.7x and 18.4x for 2026–2028. Using higher earnings forecasts from some institutions, 2026 forecast P/E could fall to approximately 19–21x; using lower forecasts, it could approach 24–25x. The current valuation is not traditionally low and still incorporates expectations for domestic recovery, international growth and volume expansion in emerging businesses. Valuation depends mainly on whether domestic medical-equipment and IVD businesses can continue to recover and whether overseas operations, minimally invasive surgery, minimally invasive intervention and animal healthcare can maintain relatively rapid growth. If 2027–2028 profit achieves the double-digit growth forecast by institutions, there is some room for valuation recovery. If domestic recovery is weaker than expected or foreign exchange continues to pressure profits, a trailing P/E of approximately 25x would still not be inexpensive. Valuation data use the September 11, 2026 closing price. September 13, 2026 was a Sunday, so there was no new A-share closing price.

4. Recent News and Announcements

4.1 2026 Interim Report: Revenue Growth and Decline in Net Profit Attributable to the Parent

Mindray Medical disclosed its 2026 Interim Report on August 29, 2026. As of June 30, 2026, operating revenue was RMB 17.747 billion, up 6.00% year on year, while net profit attributable to shareholders of the listed company was RMB 4.797 billion, down 5.37% year on year. At the end of the reporting period, the number of ordinary shareholders was 153,200, an increase of 1,118 from the previous period. Controlling shareholder Smartco Development Limited held a 26.98% stake, or 327,072,335 shares; Magnifice (HK) Limited held a 24.49% stake, or 296,951,000 shares, of which 67,600,000 shares were pledged.

4.2 Second Interim Dividend for 2026 Implemented on September 8

The company disclosed its second interim profit-distribution plan for 2026 on August 29, 2026, and its implementation announcement on August 31, 2026. The dividend was a cash payment of RMB 13.30 per 10 shares, including tax. The record date was September 7, 2026, and the ex-dividend and payment date was September 8, 2026. This was a cash-dividend distribution and not a share repurchase.

4.3 Company Responds on Future M&A Strategy; No Specific New M&A Project Announced

On September 4, 2026, media reports covered Mindray Medical’s responses regarding its strategic objectives for the next decade, its goal of entering the global top 10 medical-device companies and its M&A strategy. The company stated that it would develop around three themes—process orientation, internationalization and digital intelligence—and would continue to seek high-quality global targets, using acquisitions to supplement consumables businesses and improve its product portfolio and overseas footprint. These comments were media summaries of investor-interaction content. As of September 13, 2026, no formal disclosure had been identified regarding a specific M&A target, transaction price, transaction framework or board-review document.

4.4 Company Hosts Research Meetings for 253 Institutions

The company disclosed an investor-relations activity record on August 31, 2026. Public information indicated that it hosted 253 institutions that day, including public funds, securities firms and foreign institutions. Discussion topics primarily covered the 2026 interim report, domestic-market recovery, international growth, IVD operations, M&A strategy and emerging-business development. Institutional research meetings do not constitute operating-performance commitments, new material contracts or M&A announcements.

4.5 Disclosure of Foreign-Exchange Hedging Activities

The company disclosed an announcement and feasibility-analysis report on August 29, 2026 regarding foreign-exchange hedging activities. These activities are primarily intended to manage foreign-exchange risks arising from overseas sales and procurement, reducing the impact of exchange-rate fluctuations on operating results and financial expenses. The activities are based on actual operating needs and are not intended for speculation. This review could not fully extract all quota and authorization details from the static announcement page dated August 29, 2026. The specific limits should be based on the latest formal announcement.

4.6 Partial Release of Pledges by the Controlling Shareholder

The company disclosed an announcement on July 13, 2026 regarding the release of pledges over part of the shares held by controlling shareholder Magnifice (HK) Limited. A total of 10,200,000 shares were released, representing approximately 0.84% of total share capital and approximately 3.43% of that shareholder’s holdings. The release date was July 10, 2026 and involved 2,050,000 shares, 2,350,000 shares and 5,800,000 shares. According to the 2026 Interim Report, 67,600,000 shares held by Magnifice (HK) Limited remained pledged as of June 30, 2026. This was a change in the pledge structure and did not constitute a disposal; no related disposal plan was identified.

4.7 2022 Employee Shareholding Plan Fully Disposed of and Terminated

The company disclosed the “Announcement on Completion and Termination of Disposal under the 2022 Employee Shareholding Plan” on August 11, 2026. All 3,048,662 company shares held under the employee shareholding plan had been disposed of, and asset liquidation and distribution had been completed. The plan had been formally completed and terminated. Because the company-level performance targets corresponding to the third batch of shares were not achieved, the company cancelled the remaining 641,963 treasury shares. The shares were cancelled at the Shenzhen branch of China Securities Depository and Clearing Corporation Limited on August 7, 2026. This did not constitute a new repurchase plan.

4.8 No New Share-Repurchase Announcement Identified as of September 13

As of September 13, 2026, no new share-repurchase proposal, repurchase-progress announcement or repurchase-completion announcement issued by the company in September 2026 had been identified. The 641,963 shares cancelled on August 7 were remaining treasury shares under the employee shareholding plan and did not represent the launch of a large-scale repurchase plan in September 2026.

4.9 No 2026 Third-Quarter Earnings Guidance Disclosed as of September 13

As of September 13, 2026, no earnings guidance, preliminary earnings-growth announcement or preliminary earnings-decline announcement for the first three quarters of 2026 had been identified. The company’s latest formal operating data were operating revenue of RMB 17.747 billion and net profit attributable to shareholders of the listed company of RMB 4.797 billion as disclosed in the 2026 Interim Report. These were actual interim results, not earnings guidance or an earnings forecast.

4.10 Regulatory, H-Share Offering and Other Developments

As of September 13, 2026, no material regulatory penalty, formal investigation, material inquiry letter or exchange disciplinary action involving Mindray Medical had been identified. The company continues to implement its action plan for the dual improvement of quality and returns, advance cash and interim dividends, and conduct foreign-exchange hedging activities. The company’s application to issue H shares and list on the Main Board of the Hong Kong Stock Exchange remains in progress. The latest related announcement identified was the H-share offering and listing progress announcement dated May 11, 2026. This cannot be regarded as a completed listing; subsequent progress is subject to company announcements.

5. Share-Price Performance and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

As of September 11, 2026, Mindray Medical closed at RMB 162.73. The share price was below major short- and medium-term moving averages including MA5, MA10, MA20 and MA50, while MACD remained negative and moving-average and momentum indicators were generally weak. However, the share price remained above MA200 of approximately RMB 157.92, so the long-term trend had not been fully broken. RSI (14) was 37.02 and had not entered an extreme oversold zone, while Williams %R was -95.798, indicating some short-term oversold characteristics. The stock retreated after meeting resistance around RMB 169–172. On September 11, it fell close to the intraday low, while estimated major-fund net outflow based on transaction size was approximately RMB 154 million. Overall, the technical pattern reflected short-term consolidation and a cautious fund-flow backdrop. Medium- and long-term support should be monitored around RMB 157–159.5. The key over the coming week is whether support at RMB 161–162 holds and whether the stock can regain the dense moving-average zone at RMB 165.5–167.5.

5.3 Short-Term Outlook (Next Week; Scenario Analysis for Reference Only)

⚠️ Risk warning: The following is a subjective scenario analysis based on closing data as of September 11, 2026. It does not constitute investment advice or a definitive forecast of future share prices.

① Key Technical Levels

② Scenarios for the Coming Week (Subjective Weights, Not Statistical Probabilities)

• Range-bound consolidation (relatively higher weight, approximately 60%; this is a subjective heuristic judgment based on current technical indicators and fund flows, not a statistical probability): Price range of approximately RMB 161–167. Conditions include support emerging around RMB 161–163, turnover remaining around RMB 1.0–1.6 billion, no clear systemic decline in the pharmaceutical sector or broader market, and a narrowing of major-fund net outflows from recent levels. If this occurs, the rebound would first face resistance in the RMB 164–167 moving-average cluster.
• Weak decline (medium weight; this is a subjective heuristic judgment, not a statistical probability): Price range of approximately RMB 155–161. Conditions include closing prices breaking below the RMB 161–162 support zone for consecutive sessions, higher daily turnover with the close near the low, continued weakness in the pharmaceutical and biotechnology sector, and consecutive net outflows from extra-large and large orders. A break below RMB 161 would bring the MA200 and prior high-volume zone around RMB 158–159 into focus; a loss of approximately RMB 157 would materially weaken the technical pattern.
• Stronger rebound (low weight; this is a subjective heuristic judgment, not a statistical probability): Price range of approximately RMB 167–172. Conditions include regaining the 20-day moving average around RMB 165.5, followed by a high-volume breakout above RMB 167.5, daily turnover materially exceeding recent averages, major funds shifting from consecutive net outflows to consecutive net inflows, and a simultaneous rebound in the medical-device or pharmaceutical sector. A decisive break above RMB 167.5 would bring the RMB 170–172 prior-high zone into focus. Without a corresponding increase in volume, the validity of the breakout should be treated cautiously.

③ Fund-Flow and Liquidity Background

As of September 11, 2026, Mindray Medical had a total market capitalization of approximately RMB 197.2 billion and approximately 1.211 billion shares outstanding in the free float. The daily turnover rate was 0.60%; it ranged from approximately 0.54% to 0.93% over the latest five trading days, averaging approximately 0.67%, and averaged approximately 0.78% over the latest 10 trading days. Average turnover value was approximately RMB 1.34 billion over the latest five days and approximately RMB 1.56 billion over the latest 10 days. The stock is not a low-liquidity small-cap name, so slippage risk under normal trading conditions is relatively limited. However, with relatively low turnover and a concentrated shareholder structure, the share price may still move rapidly in the short term if large-order funds move in the same direction. According to Tonghuashun’s first-quarter 2026 data, the top 10 free-float shareholders held approximately 809 million shares in aggregate, representing approximately 66.80% of free-float shares. The two largest shareholders, Smartco Development Limited and Magnifice (HK) Limited, together held more than 50%; Hong Kong Securities Clearing Company, public-fund ETFs, the National Social Security Fund and basic pension funds also appeared among the top 10 free-float shareholders. This concentration data was as of March 31, 2026, and is materially outdated relative to the September 11, 2026 market conditions. Holdings may have changed during the period, so it should not be treated as the current real-time ownership structure. The number of shareholders was approximately 153,200 as of June 30, 2026, up approximately 0.74% from March 31, 2026, not yet indicating a clear ongoing concentration trend.

A measurable volume-confirmation signal would be as follows: if the share price regains RMB 165.5–167.5 while daily turnover reaches RMB 1.8 billion or more for consecutive sessions—approximately 1.3x the five-day average—this could be viewed as an observation signal that the rebound has volume confirmation. If turnover also materially exceeds RMB 1.8 billion when the price breaks below RMB 161–162, investors should be alert to a failure of support and accelerated short-term fund outflows.

④ Points to Monitor (Observation Framework Only, Not Trading Instructions)

• Observe whether support around RMB 162 holds and whether RMB 161 is lost on a closing basis; this is an observation framework, not a trading instruction.
• Observe whether the dense moving-average zone at RMB 165.5–167.5 can be regained; this is an observation framework, not a trading instruction.
• Observe whether net outflows from extra-large and large orders narrow and whether they can turn into consecutive net inflows; this is an observation framework, not a trading instruction.
• Observe whether turnover can expand to more than RMB 1.8 billion for consecutive sessions in conjunction with a price breakout; this is an observation framework, not a trading instruction.

The above scenario analysis is based on closing data as of September 11, 2026, and calculations using historical prices and technical indicators. Short-term share prices may also be affected by news, fund flows, broader-market conditions and other factors. Technical indicators are inherently lagging and limited. This analysis does not guarantee actual future performance and does not constitute a buy or sell recommendation. Investors should independently assess the latest market information and bear investment risks themselves.

6. Industry Landscape and Competitor Analysis

6.1 Industry Conditions

The medical-device industry comprises multiple submarkets, including patient monitoring, anesthesia, respiratory care, IVD, ultrasound, imaging, minimally invasive surgery, intervention and animal healthcare. Technical barriers, competitive structures and procurement mechanisms differ substantially across these areas. The industry generally has barriers involving R&D, clinical validation, registration approval, quality-system certification and after-sales service. Hospital installations, channel services, training and maintenance, consumables supply and software upgrades create a degree of network effect.

6.2 Competitive Landscape

• International brands retain advantages in segments of the high-end medical-device market. GE HealthCare, Siemens Healthineers, Philips, Medtronic, Dräger, Abbott and Roche have strong brand and technological influence in selected high-end imaging, monitoring, testing, anesthesia and interventional fields.
• Domestic substitution continues to advance. Chinese companies including Mindray, United Imaging, SonoScape, Edan and Yuwell have developed competitive advantages in different subsegments. Government procurement, equipment replacement and centralized procurement are promoting localization while compressing pricing room for some standardized products.
• Hospital procurement is typically affected by tendering, centralized procurement, hospital budgets, DRG/DIP reforms, equipment-replacement cycles and medical-service price governance. Standardized equipment and IVD products face some pricing pressure.
• Mindray’s integrated competitive advantage comes from coordination across product lines. It can sell monitoring, anesthesia, ultrasound, IVD, imaging, operating-room products and digital-intelligence solutions to the same hospital, enabling cross-selling and integrated procurement.
• The company is transitioning from a single-equipment supplier toward a provider of “equipment + consumables + software + AI + integrated solutions.” It is expanding its overall competitiveness through R&D and manufacturing bases, overseas channels, localized operations and its hospital-installed base.

6.3 Major Competitors

The core differences between Mindray and comparable domestic companies lie in product breadth, comprehensive hospital coverage and integrated solutions. United Imaging is more concentrated in high-end imaging and radiotherapy; SonoScape focuses more on ultrasound and endoscopy; Edan covers niche scenarios including monitoring, women’s and children’s healthcare and ECG; and Yuwell is more oriented toward home and consumer healthcare. Compared with international companies, Mindray still faces competition in brand, technological accumulation and global market share in certain high-end imaging, monitoring, anesthesia, respiratory-care, IVD and interventional fields. However, its coordination across products, domestic substitution, localized service and “equipment + reagents and consumables + software” closed loop form differentiated advantages.

7. Risk Factors

• Risk that domestic recovery falls short of expectations: Domestic revenue declined 22.97% year on year in 2025 and was still down 1.61% year on year in the first half of 2026. If hospital budgets, equipment replacement, DRG/DIP reforms or medical-service price governance continue to affect procurement timing, recovery in domestic revenue and equipment-business profit could be delayed.
• IVD centralized-procurement and price-competition risk: IVD was the company’s largest revenue segment in 2025, generating RMB 12.241 billion, or 36.78% of revenue. The company has also been affected by centralized volume-based procurement of reagents and mutual recognition of test results. If centralized procurement expands or price cuts exceed expectations, gross margins and recurring revenue from instruments, reagents and consumables could be pressured.
• Risk that overseas-business profitability falls short: Overseas revenue accounted for approximately 53% of 2025 revenue and increased 7.40% year on year; international revenue grew 13.67% year on year in the first half of 2026. However, overseas markets continue to face brand competition, channel development, product certification, local-service costs and foreign-exchange volatility. Revenue growth may not translate proportionately into net-profit growth.
• Foreign-exchange risk: Both overseas sales and procurement are affected by exchange rates. Profit remained under pressure from related factors in the first half of 2026, and the company has initiated foreign-exchange hedging. If exchange-rate volatility persists or hedging effectiveness is limited, revenue translation, financial expenses and net profit attributable to the parent could be affected.
• Supply risk involving core components and special raw materials: Overall supplier concentration is low, with the five largest suppliers accounting for only 6.06% of procurement. However, high-performance chips, sensors, core imaging components, precision optical components and special reagent raw materials may involve long certification cycles, limited alternatives or import dependence. Diversified overall suppliers do not mean that supply risks for key components have been eliminated.
• Receivables and inventory turnover risk: At the end of 2025, accounts receivable were RMB 3.408 billion and inventory was RMB 5.004 billion, with inventory turnover days of approximately 133.03 days. The balance of domestic receivables aged more than 360 days was relatively high, and the related bad-debt provision ratio reached 97.16%. Further delays in collections from hospitals or channels could increase impairment and cash-flow pressure.
• Emerging-business and M&A execution risk: Emerging businesses including minimally invasive surgery, minimally invasive intervention and animal healthcare generated RMB 5.378 billion in 2025, accounting for approximately 16.16% of revenue. Although the company has stated that it will use acquisitions to supplement consumables businesses and its overseas footprint, no specific transaction plan has been announced. Future risks may include target selection, integration, R&D commercialization and higher-than-expected investment expenses.
• Valuation and market-volatility risk: As of September 11, 2026, the company’s trailing P/E was approximately 24–25x. The current share price already incorporates expectations for domestic recovery, overseas growth and volume expansion in emerging businesses. If profit growth is below institutional forecasts, or if the share price falls below technical observation zones such as RMB 161–162 and RMB 157–159.5, valuation and market sentiment could come under simultaneous pressure.

8. Conclusion and Outlook

Mindray Medical’s medium- and long-term growth thesis rests primarily on three factors: revenue recovery as domestic medical-equipment procurement gradually recovers, continued overseas expansion, and increasing contributions from emerging businesses such as minimally invasive surgery, minimally invasive intervention and animal healthcare, together with recurring purchases of IVD consumables. International revenue maintained relatively rapid growth in the first half of 2026, while second-quarter revenue and profit growth returned to positive territory, indicating marginal operating improvement. The company continues to advance its process-oriented, internationalization and digital-intelligence strategies, and plans to use acquisitions to supplement consumables businesses and improve its product portfolio and overseas footprint. However, as of September 13, 2026, it had not disclosed a specific M&A target or transaction plan.

Future earnings recovery will still depend on whether the domestic business can stabilize, whether IVD pricing pressure eases, whether overseas revenue growth converts into profit, and whether volume expansion in emerging businesses and high-end product upgrades can improve the product mix. The institutional sample forecasts net profit attributable to the parent of approximately RMB 8.447 billion in 2026, RMB 9.647 billion in 2027 and RMB 10.918 billion in 2028. These forecasts are not company guidance, and forecasts differ among institutions. The current valuation is not traditionally low. If profit recovery meets expectations, valuation may be gradually absorbed by earnings growth; if domestic recovery, foreign-exchange conditions or overseas expansion are weaker than expected, valuation pressure could persist.

From a technical and trading perspective, the share price retreated after meeting resistance in the RMB 169–172 area. RMB 161–162 and RMB 157–159.5 correspond to short-term and more important support zones, respectively, while RMB 164–167.5 is the main moving-average resistance zone. Technical indicators reflect market conditions only through September 11, 2026 and cannot replace fundamental and valuation analysis. Investors should focus on changes in domestic revenue and profit margins, the overseas business’s profit contribution, cash flow and receivables quality, and whether the company discloses substantive progress on M&A or the H-share offering.

Data Sources

• Mindray Medical (300760)_Company Announcements_Mindray Medical: 2025 Annual Report_Sina Finance_Sina.com
• https://www.xinhuanet.com/health/20260403/df10dc85557b48e79647333f42d35933/c.html?utm_source=openai
• [Overview

1. Project Background

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as “Mindray Medical”) was established in 1991](https://www.mindray.com/content/dam/xpace/zh/media-center/press-center/news/mindray-guangming-hematology-calibration-quality-control-workshop-environmental-impact-assessment-announcement/mindray-guangming-hematology-calibration-quality-control-workshop-environmental-impact-report-draft-1.0-cn.pdf?utm_source=openai)

• Mindray Medical (300760)_Company Announcements_Mindray Medical: 2024 Annual Report_Sina Finance_Sina.com
• https://reportify.cn/transcripts/1236264939597991936?utm_source=openai
• 2026: Witnessing a More Open, Intelligent and Caring Mindray Together - Mindray Medical
• Mindray Medical: 2025 Annual Report Summary_Stock Channel_Stockstar
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. 2025 Interim Report
• Xiaojingji—Mindray Medical
• Frequently Asked Questions
• Shenzhen SonoScape Medical Corp., Ltd.
• China’s Medical Imaging Equipment Industry: Low Market Concentration, with United Imaging and Mindray Showing Relatively Strong Revenue Advantages_China Research Report Network
• Yuwell Medical
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: 2025 Annual Report Summary_Sina Finance_Sina.com
• Mindray Medical (300760)_Company Announcements_Mindray Medical: 2026 Interim Report_Sina Finance_Sina.com
• Mindray Medical (300760) 2026 Interim Results Review: Domestic Business Bottoming Out and Stabilizing; International Revenue Continuing Rapid Growth_Sina Finance
• 2026 Interim Results Review: Earnings Recovery, Rapid Growth in International and Emerging Businesses—Orient Securities | FXBG
• Southwest Securities—Mindray Medical (300760) 2025 Annual Results Review: Domestic Business Gradually Bottoming Out and Stabilizing; International Revenue Continuing to Grow—260405.pdf
• Mindray Medical (300760) Earnings Forecast_F10_Tonghuashun Financial Services
• Earnings Forecast—Stock Data—Data Center—Stockstar
• Mindray Medical (300760) 2026 Interim Results Review: Q2 Operations Accelerate; Overseas Growth and Emerging Businesses in Tandem_Sina Finance
• Huachuang Securities: “Mindray Medical (300760) 2026 Interim Results Review”—FXBG
• Earnings Forecast
• Mindray Medical (300760) Analyst Consensus Estimates_Market Sentiment_Investing.com
• Mindray Medical sz300760 Share Price, Market Data, Live Stream, News, Financial Reports and Data—Aigu Shares
• Mindray Medical (300760) Latest Price, Real-Time Chart, Share-Price Analysis and Forecast_Investing.com
• Mindray Medical (300760)—Historical Trading Data | Dabanke
• Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A Technical Analysis (300760)
• Mindray Medical (300760)_Fund Flows_Stockstar
• Mindray Medical (300760)—Detailed Share Capital and Shareholders
• Mindray Medical (300760)—Detailed Share Capital and Shareholders

This report was automatically retrieved, compiled and generated by AI based on information from public channels. Information is current through the September 11, 2026 close; this report primarily uses the closing-market data methodology of Dabanke, with a closing price of RMB 162.73. Minor discrepancies exist among market-data sources. Investing displayed RMB 163.08 on the same day, possibly due to refresh timing, adjustment methodology or data-processing differences. There may be differences in timeliness; specific data should be based on the company’s formal announcements and authoritative data terminals. This report is for information organization and research reference only and does not constitute investment advice. Investors should make independent judgments and bear investment risks themselves.